HC Wainwright Reaffirms Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 122.22% from the company’s previous close. HC Wainwright also issued estimates for Anixa Biosciences’ Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

Other equities analysts also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, January 22nd. Maxim Group assumed coverage on shares of Anixa Biosciences in a research report on Friday, March 21st. They set a “buy” rating and a $10.00 price objective on the stock.

Anixa Biosciences Stock Performance

NASDAQ ANIX opened at $3.15 on Tuesday. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20. The stock has a market cap of $101.42 million, a PE ratio of -8.08 and a beta of 0.86. The stock’s 50 day moving average is $2.95 and its 200 day moving average is $3.01.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). On average, analysts forecast that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Transactions at Anixa Biosciences

In related news, CEO Amit Kumar purchased 43,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, January 17th. The stock was bought at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the purchase, the director now directly owns 922,334 shares in the company, valued at $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 75,289 shares of company stock worth $177,021. 25.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Focus Partners Wealth purchased a new stake in shares of Anixa Biosciences in the 4th quarter worth $162,000. LPL Financial LLC lifted its stake in Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after acquiring an additional 11,633 shares during the period. Westside Investment Management Inc. lifted its stake in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the period. Jane Street Group LLC bought a new position in Anixa Biosciences during the 4th quarter worth about $67,000. Finally, Prosperity Wealth Management Inc. purchased a new position in Anixa Biosciences during the 4th quarter valued at about $54,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.